Rezolute, Inc. (RZLT)
NasdaqCM · USD · Healthcare · Biotechnology
$3.82 (-0.91%) as of
Key statistics
- Market cap
- 369.48M
- Forward P/E
- -8.15
- EPS (TTM)
- -0.7400
- Dividend yield
- 0.00%
- 52-week range
- 1.0700 – 11.4570
- Beta
- 0.54
- Profit margin
- 0.00%
- Analyst target
- $9.80
- Volume
- 1.54M
About Rezolute, Inc.
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Redwood City, CA, United States
- Employees
- 58
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.